ROS1 and non-small cell lung carcinoma: A large study of NGS-based genotyping, with the hybrid-capture-based Guardant360x assay, in ROS1-positive NSCLC patients revealed high concordance (100% for 7 patients from 54) between plasma and corresponding tissue samples.